229614-55-5

Basic information

• Product Name: Peramivir
• Synonyms: Peramivir;(1S,2S,3R,4R)-3-(1-acetaMido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid;3(R)-[1(S)-AcetaMido-2-ethylbutyl]-4(R)-guanidino-2(S)- hydroxycyclopentane-1(S)-carboxylic acid;(1S,2S,3S,4R)-3-[(1S)-1-AcetaMido-2-ethylbutyl]-4-[(diaMinoMethylene)aMino]-2-hydroxycyclopentanecarboxylic acid;PERAMIVIRUM
• CAS NO: 229614-55-5
• Molecular Formula: C₁₅H₂₈N₄O₄
• Molecular Weight: 328.41
• EINECS: 1308068-626-2
• Product Categories: Amines;Chiral Reagents;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Pharmaceuticals
• Mol File: 229614-55-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.39g/cm³
• Refractive Index: 1.613
• CAS DataBase Reference: Peramivir(CAS DataBase Reference)
• NIST Chemistry Reference: Peramivir(229614-55-5)
• EPA Substance Registry System: Peramivir(229614-55-5)

Safety Data

• Hazardous Substances Data: 229614-55-5(Hazardous Substances Data)

Usage

Description

Peramivir is an antiviral medication specifically designed to combat influenza infections. It functions by inhibiting the neuraminidase enzyme, which is essential for the replication and spread of the influenza virus within the host. This action helps to reduce the severity and duration of flu symptoms, making it a valuable pharmaceutical compound in the treatment of both human and avian influenza.

Uses

Used in Pharmaceutical Industry:
Peramivir is used as an antiviral agent for the treatment of influenza. It targets the neuraminidase enzyme, which is crucial for the virus's ability to infect new cells and spread within the host. By inhibiting this enzyme, Peramivir helps to reduce the severity and duration of flu symptoms, making it an important tool in managing both human and avian influenza cases.

Pharmaceutical Applications

An intravenously administered neuraminidase inhibitor currently under investigation for the treatment of influenza infections in normal and high-risk patient populations. No drug interactions of note have yet been identified.

InChI:InChI=1/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1

Upstream product

• 168683-02-1 (1S,4R)-(-)-methyl-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopent-2-ene-1-carboxylate 
• 229613-83-6 (–)-methyl (1S,4R)-4-aminocyclopent-2-ene-1-carboxylate hydrochloride 
• 229614-17-9 (-)-methyl (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-amino-2-hydroxycyclopentanecarboxylate hydrochloride 
• 29671-92-9 chloroformamidine hydrochloride 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 
• 1988779-13-0 (1S,2S,3S,4R)-methyl 3-((S)-1-amino-2-ethylbutyl)-4-(tert-butoxycarbonylamino)-2-hydroxycyclopentanecarboxylate 
• 229613-93-8 (+)-methyl (3aR,4R,6S,6aS)-4-[(tert-butoxycarbonyl)-amino]-3-(1-ethylpropyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]isoxazole-6-carboxylate 
• 1404223-97-7 (1S,4R)-methyl-4-(2,3-bis(tert-butoxycarbonyl)guanidino)cyclopent-2-ene-carboxylate 
• 383910-27-8 (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)-imino]methyl}amino)-2-hydroxycyclopentanecarboxylic Acid 
• 97-96-1 2-Ethylbutyraldehyde 
• 1116682-13-3 C₁₄H₂₅N₂O₄^(1-)*Na⁽¹⁺⁾ 

Relevant articles and documents

Facile synthesis of the neuraminidase inhibitor peramivir

An improved and convenient synthetic route for the synthesis of peramivir has been developed with a total 34% yield. The process was improved from previous methods in three key reaction steps including 1,3-dipolar cycloaddition, reductive ring cleavage of

(1S, 2S, 3S, 4R)-3-Y(1S)-1-ACETYLAMINO-2-ETHYL-BUTYL¨-4-GUANIDINO-2- HYDROXYL-CYCLOPENTYL-1-CARBOXYLIC ACID HYDRATES AND PHARMACEUTICAL USES THEREOF

The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.